

3RD MEETING OF WEST EUROPEAN SOCIETIES OF BIOLOGICAL PSYCHIATRY

PERSONALISED MEDICINE IN PSYCHIATRY:
FROM DREAMS TO REALITY
2 - 4 June 2010, Berlin, Germany

WWW.WEBP2010EU
PRELIMINARY PROGRAMME

Rathaus Schöneberg

A joint meeting of the



BCNP
Belgian College of Neuropsychopharmacology and Biological Psychiatry



AFPB
Association Française de Psychiatrie Biologique



DGBP
Deutsche Gesellschaft für Biologische Psychiatrie



ÖGPB
Österreichische Gesellschaft für Neuropharmakologie und Biologische Psychiatrie




SGBP
Schweizerische Gesellschaft für Biologische Psychiatrie



SUPPORTED BY THE WORLD FEDERATION OF SOCIETIES OF BIOLOGICAL PSYCHIATRY

Rathaus Schöneberg - Second Floor



JOHN-F.-KENNEDY-PLATZ

Organisation

The Third Meeting of West European Societies of Biological Psychiatry is a joint meeting of the Belgian, French, German, Austrian and Swiss Societies.



The Third Meeting of West European Societies of Biological Psychiatry is supported by the World Federation of Societies of Biological Psychiatry.



Meeting Chairs

Baylé Franck, *Paris, France*
Dierick Michel, *Gent, Belgium*
Falkai Peter, *Göttingen, Germany*
Hatzinger Martin, *Basel, Switzerland*

Organising Committee

Aubry Jean-Michel, *Genève, Switzerland*
Baylé Franck, *Paris, France*
Cosyns Paul, *Antwerp, Belgium*
Dierick Michel, *Gent, Belgium*
Falkai Peter, *Göttingen, Germany*
Hatzinger Martin, *Basel, Switzerland*
Heinz Andreas, *Berlin, Germany*
Lentner Susanne, *Vienna, Austria*
Llorca Pierre Michel, *Clermont-Ferrand, France*
Mesotten Frans, *Bilzen, Belgium*
Mueller Norbert, *München, Germany*
Thibaut Florence, *Rouen, France*

Scientific Committee

M. Annseau, *Liège, Belgium*
Aubry Jean-Michel, *Genève, Switzerland*
Baylé Franck, *Paris, France*
Cosyns Paul, *Antwerp, Belgium*
Dierick Michel, *Gent, Belgium*
Falkai Peter, *Göttingen, Germany*
Hatzinger Martin, *Basel, Switzerland*
Heinz Andreas, *Berlin, Germany*
Lentner Susanne, *Vienna, Austria*
Llorca Pierre Michel, *Clermont-Ferrand, France*
Mesotten Frans, *Bilzen, Belgium*
Mueller Norbert, *München, Germany*
Thibaut Florence, *Rouen, France*

Welcome Address

Dear Colleagues,

We take great pleasure in inviting you to Berlin, a city located at the heart of the crossroads between Eastern and Western Europe! Until two decades ago, this city typified the separation between political systems and ideas in Europe and now is a symbol of unification and new hope.

Psychiatry in Berlin has a dramatic history, ranging from the first attempt to integrate neurology and psychiatry in the Charité in the 19th century with Wilhelm Griesinger, who also fought stigmatisation of mentally ill patients, to the organisation of the murder of at least two hundred thousand patients during National Socialism and to the recovery and rise of a patient-oriented, evidence-based and scientifically active discipline.

Currently, Berlin is a vibrant city with a strong neuroscience and psychosocial research focus and a city open for migrants and new social trends and artistic developments.

We welcome you to our city and hope you have time to explore Berlin and enjoy the Meeting.

A. Heinz (chair) , K. Charlet, M. Rapp

P. Falkai

Local Organising Committee

President of the DGBP

- 13.00 Registration
- 15.00 **Satellite Symposium** **BVV-Saal**
- 16.30 Coffee break and poster viewing
- 16.45 **Opening of the 3rd WEBP** **WB-Saal**
A. Heinz (D) and P. Falkai (D)
- 17.00 **Plenary Lecture: Genetics in schizophrenia** **WB-Saal**
I1 *F. Thibaut (F), President of the WFSBP
and the Presidents of the Societies*

Chairs: A. De Nayer (B) and F. Schneider (D)
- 18.00 **Parallel Symposia**
- Neurophysiology** **TH-Saal**
Chairs: B. Glenthøj (DK) and C. Baeken (B)
- I2** Psychophysiological disturbances in psychoses: Focus on gender issues
V. Kumari (UK)
- I3** Electrophysiological disturbances in longitudinal studies of first-episode antipsychotic-naïve patients with schizophrenia: Relation to treatment and outcome
B. Oranje (DK)
- I4** Essential principles of clinical neurocognitive neurophysiology: Practical guidelines to avoid error and pitfalls
G. Otte (B)
- I5** Clinical evidence for rTMS in the treatment of depression and its application in a private practice setting
F. Rachid (CH)

Social cognition

2113-Saal

Chairs: B. Sabbe (B) and P. Vuilleumier (CH)

- I6** Understanding other people: Cognition, social cognition and schizophrenia
P.W.R. Woodruff (UK)
- I7** Psychobiology of social interaction: How social stress and neuropeptides influence pro- and antisocial behavior
B. von Dawans (D)
- I8** Antisocial behaviour? Comparing the neural correlates of monitoring own and other's actions in Individuals with psychopathy
W. Hulstijn (B & NL)

WB-Saal

Joint Symposium AGNP and DGBP: Personalized medicine in psychiatry

Chairs: E. Holsboer-Trachsler (CH) and P. Falkai (D)

- I10** Functional imaging in the prediction of differential therapy with neuroleptics (DGBP)
O. Gruber (D)
- I11** Influence of Oxytocin on social cognitive functions (DGBP)
S.C. Herpertz (D)
- I12** Treatment resistant depression – which patients might be treated with deep brain stimulation in the future? (AGNP)
T. Schlaepfer (D)

Mirror neurones and empathy

Chairs: E. Constant (B) and Ph. Nuss (F)

- I13** Empathy and the mirror neuron system: Developmental aspects and lessons from autism
M. Schulte-Rüther (D)
- I14** Age-related improvement in social functioning and motor simulation within the mirror neuron system in autism
M. Thioux (NL)
- I15** Impairments of empathy and of the “who system” in psychopathology
N. Georgieff (FR)

19.30

Get-Together Party at the Congress Centre (exhibition area)

09.00

Plenary Lecture: Gene environment interactions

WB-Saal

I16 *K.P. Lesch (D) and A. Fischer (D)*

I17

Chairs: A. Malafosse (CH) and S. Claes (B)

10.00

Coffee break and poster viewing

10.30

Parallel Symposia

Neurobiology of psychotherapy

BVV-Saal

Chairs: S.C. Herpertz and A. Buchheim (A)

- I18** Neurobiology and psychotherapy: What do we know, and what is the potential use and harm of neurobiological research for psychotherapy?
F. Caspar (CH)
- I19** Neural correlates of attachment in chronically depressed patients before and after 15 months of psychodynamic psychotherapy
A. Buchheim (A)
- I20** Imaging studies in psychotherapy research: The example of CBT interventions
T. Kircher (D)
- I21** Neuronal correlates of psychotherapeutic effects in borderline personality disorder
S.C. Herpertz (D)
- Suicide**

WB-Saal

Chairs: K. van Heeringen (B) and P. Courtet (F)

- I22** Suicidal brains: A systematic review of neuroimaging studies of suicidal behaviour
K. van Heeringen (B)
- I23** Genetic epidemiology of suicide: An overview of family, twin, adoption, migrant, geographic, and surname studies of suicide
M. Voracek (A)
- I24** An update on candidate genes for suicide
D. Rujescu (D)
- I25** Suicidal ideation during antidepressant treatment: Clinical and genetic issues
N. Perroud (CH)

Symposium European pharmacists

2113-Saal

Chairs: J. Reyntens (B) and P. Martin (F)

- I26** Exploring the impact of medication information for psychiatric patients at hospital discharge: The GIPPOZ-study
S. Desplenter (B)
- I27** Four years evaluation on schizophrenic patients who followed a therapeutic education program called 'Drugs workshops'
S. Baudry (F)
- I28** Antipsychotic polypharmacy: A risk for high-dose antipsychotic prescription?
J. Reyntens (B)
- I29** Drug interactions in psychiatric care: A practical approach
V. Foulon (B)
- I30** Pain mental health, a feature?: The viewpoint of the pharmacist
I. De Beauchamps (F)

Mania and ADHD: Common pathophysiology, common symptomatology and common treatment

TH-Saal

Chairs: U. Hegerl (D) and M.E. Keck (CH)

- I31** EEG vigilance and EEG phenotypes in ADHD: Implications for personalized medicine
M. Arns (NL)
- I32** Vigilance and mood regulation
U.M. Hemmeter (CH)
- I33** Genes and hormones in ADHD and affective disorders
H. Himmerich (D)
- I34** Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate
T. Bschor (D)
- I35** Manic behaviour as an autoregulatory attempt to stabilize vigilance
U. Hegerl (D)

12.00 Lunch and poster viewing

- 13.30 **Plenary Lecture: Imaging** **WB-Saal**
I36 C. Büchel (D) and R. Spanagel (D)
I37 Chairs: R. Lanzenberger (A) and O. Gruber (D)
- 14.30 **Satellite Symposium (Servier)** **BVV-Saal**
 Chairs: M. Dierick (B) and F. Baylé (F)
- 16.00 Coffee break and poster viewing
- 16.30 **Parallel Symposia**
- Therapeutic interventions in affective disorders** **BVV-Saal**
 Chairs: D. Souery (B) and E. Holsboer-Trachsler (CH)
- I38** Differential indication of phytotherapeutics for the depressive syndrome: A translational approach
 A. Eckert (CH)
- I39** Sleep deprivation: Therapeutic and research tool in depression
 J. Beck (CH)
- I40** Switching to a different class of antidepressant is not associated with better response or remission in antidepressant failure
 D. Souery (B)
- I41** Pharmacogenetics of antidepressant response
 A. Drago (IT)
- I42** Biomarkers and pharmacogenetics of the HPA regulation and antidepressant response
 M. Ising (D)
- New antedementias** **TH-Saal**
 Chairs: E. Thiery (B) and W. Maier (D)
- I43** New antedementias: An overview
 P. De Deyn (B)
- I44** Recommended designs for disease modifying drugs studies in Alzheimer Disease - Importance of surrogate biomarkers
 S. Bakchine (F)
- I45** Aiming at an optimal neuropsychological battery in future antedementia research
 E. Salmon (B)
- I46** Dimebolin and other new antedementias: From pharmacological profile to phase III studies
 L. Frölich (D)

Pharmacogenomics

2113-Saal

Chairs: P. Gorwood (F) and J.M. Maloteaux (B)

- I47** Genetics versus pharmacogenetics of schizophrenia
P. Gorwood (F)
- I48** Pharmacogenetics of antidepressant treatment outcome
Results from recent genome-wide studies
M. Ising (D)
- I49** Inducible expression of dopamine D_{2L} receptor in cells, as a useful tool to study antipsychotics with partial agonist properties
B. Köner (B)
- I50** A haplotype of the norepinephrine transporter (net) gene SLC6A2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)
N. Ramoz (F)

Therapeutic interventions in schizophrenia

WB-Saal

Chairs: J. Peuskens (B) and F. Mesotten (B)

- I51** Novel antipsychotics in the treatment of children and adolescents
C. Correll (US)
- I52** Intervention in the prodromal phase and first psychotic episode
A. Riecher-Rössler (CH)
- I53** Physical health considerations in the treatment with antipsychotic agents
Recommendation for diagnoses and treatment
M. De Hert (B)
- I54** Evaluation of outcome in the treatment of schizophrenia
P.M. Llorca (F)

- 09.00 **Satellite Symposium** **BVV-Saal**
Chair: P. Falkai (D)
- 10.30 Coffee break and poster viewing
- 11.00 **Plenary Lecture: The genetics of psychoses: Bipolar or schizophrenic, does it matter?** **WB-Saal**
I55 *J. Mendlewicz (B) and M. Nöthen (D)*
I56 *Chairs: M. Dierick (B) and F. Schürhoff (F)*
- 12.00 Lunch and poster viewing
- 13.30 **Parallel Symposia**
- Measuring interaction in functional imaging** **TH-Saal**
Chairs: A. Heinz (D) and W. Strik (CH)
- I57** **Reward processing in schizophrenia**
A. Heinz (D)
- I58** **Gene-environment interactions**
M. Smolka (D)
- I59** **Interactions in the language system and psychosis**
W. Strik (CH)
- I60** **Hyperscanning**
A. Meyer-Lindenberg (D)
- Neuroplasticity and neuroimmunology in mood disorders** **BVV-Saal**
Chairs: J.M. Aubry (CH) and N. Müller (D)
- I61** **Monocyte gene expression fingerprints in major depression and bipolar disorder**
H. Drexhage (NL)
- I62** **Inflammation and immunity in psychiatric disorders: Consequences for therapy**
N. Müller (D)
- I63** **The phosphoinositide 3- kinase/AKT signaling axis: Role in major depression**
F. Karege (CH)
- I64** **Brain Derived Neurotrophic Factor (BDNF) in depression – the state-of-the-art**
A. Delini-Stula (CH)

Epigenetics in neuroscience and psychiatry

WB-Saal

Chairs: S. Bleich (D) and A. Malafosse (CH)

- I65** Epigenetics in neuroscience and psychiatry – An introduction
H. Frieling (D)
- I66** Abberant DNA methylation in addictive behaviours
B. Lenz (D)
- I67** Psychiatric implications of RNA editing in the serotonergic system
D. Walther (D)
- I68** Genetic and epigenetic analysis of SSAT gene dysregulation in suicidal behavior
M. Guipponi (CH)

Significance of glial cell pathology in psychiatric disorders

2113-Saal

Chairs: B. Bogerts (D) and A. Schmitt (D)

- I69** Significance of glia cell dysfunction in schizophrenia
B. Bogerts (D)
- I70** Stereological investigations of neurons and glia cells in the hippocampus of psychiatric disorders
A. Schmitt (D)
- I71** Glial abnormalities in schizophrenia: A proteomic overview
D. Martins-de-Souza (D)
- I72** Combined MRS/fMRI investigations of abnormal glial functioning in major depression
M. Walter (D)

15.00 Coffee break and poster viewing

Chairs: W. Gaebel (D) and K. Do Cuénod (CH)

- 01** Systematic screening for attention deficit / hyperactivity disorders (ADHD) in parents of children with ADHD
Caci H., Bouchez J., Baylé F. (F)
- 02** Redox dysregulation affects parvalbumin interneurons and neural synchrony in brain regions affected in schizophrenia
Steullet P., Cabungcal J.H., Kulak A., Cuenod M., Do K.Q. (CH)
- 03** Pegylated human interferon alpha 2a does not induce depression-associated changes in mice
Kosel M., Bilkei-Gorzo A., Zawatzky R., Zimmer A., Schlaepfer T.E. (D, US & CH)
- 04** Revival of the dead: Tryptophan hydroxylase 1 in alcoholism
Walther D.J., Vowinkel J., Paulmann N. (D)
- 05** High frequency stimulation and pharmacological inactivation of the globus pallidus and the nucleus entopeduncularis differentially affect quinpirole-induced compulsive checking in rats
Djodari-Irani A., Klein J., Banzhaf J., Juckel G., Heinz A., Kupsch A., Morgenstern R., Winter C. (D)
- 06** Can eye help you? Investigations of the effects of 'social gaze' on mechanisms of action control in healthy controls and individuals with high-functioning autism
Schilbach L., Eickhoff S.B., Cieslik E., Shah N.J., Fink G.R., Vogeley K. (D)
- 07** sAPP_β is significantly correlated with sAPP_α and this challenges hypotheses about the molecular pathogenesis of Alzheimer's disease (AD)
Alexopoulos P., Tsolakidou A., Eisele T., Westerteicher C., Arnold A., Förstl H., Kurz A., Pernecky R. (D)
- 08** Effects of age and sex on concentrations of glutamate and choline in the human brain
Wirth C., Schubert F., Bierbrauer J., Gallinat J. (D)
- 09** Genetic variation of the extracellular matrix proteoglycan brevican affects human prefrontal cortex function and white matter ultrastructure
Schott B.H., Richter S., Wüstenberg T., Franken G., Rodriguez-Fornells A., Münte T.F., Gundelfinger E.D., Seidenbecher C. I. (D & E)

Chairs: N. Müller (D) and M. Hatzinger (CH)

- 010** Cue-induced brain activation mediates subsequent relapse in abstinent alcoholics
Beck A., Wrase J., Schlagenhauf F., Wüstenberg T., Vollstädt-Klein S., Hermann D., Smolka M.N., Ruf M., Weber-Fahr W., Flor H., Mann K., Braus D.F., Heinz A. (D)
- 011** Differences in reward processing across the lifespan
Rapp M.A., Schlagenhauf F., Mell T., Beck A., Heinz A. (D)
- 012** Neuronal functionality of reinforcement learning in adolescents
Schmidt D. (D)
- 013** Statin use and depression in patients with coronary heart disease: Longitudinal data from the heart and soul study
Otte C., Zhao S., Whooley M.A. (D & USA)
- 014** Glutamate in pregenual anterior cingulate cortex predicts its altered resting state functional connectivity with anterior insula and disease severity in patients with major depression
Horn D.I., Buchmann J., Kaufmann J., Osoba A., Zierhut K., Schiltz K., Bogerts B., Walter M. (D)
- 015** Association of ADHD4 genetic variants with alcohol dependence risk and related phenotypes: Results from a larger multicenter association study
Preuss U.W., Ridinger M., Rujescu D., Samochowiec J., Fehr C., Wurst F.M., Koller G., Bondy B., Wodarz N., Debniak T., Grzywacz A., Soyka M., Zill P. (D, PL, A & CH)
- 016** Magnetic resonance imaging of regional cerebral blood flow in schizophrenic patients with persistent auditory verbal hallucinations
Wolf R.C., Herrnberger B., Frasch K., Sambataro F., Schmid M., Vasic N., Schönfeldt-Lecuona C., Osterfeld N.D. (D & USA)
- 017** The 'sex-effect' or: How to correlate anticorrelated networks – an fMRI study
Metzger C., Schneider F., Eckert U., Haila N., Buchmann J., Horn D., Steiner J., Tempelmann C., Bogerts B., Walter M. (D)
- 018** Higher intensity of craving in abstinent type II alcohol dependent patients
Pinto E., Reggers J., Gorwood P., Boni C., Scantamburlo G., Pitchot W., Ansseau M. (B & F)

Imaging genetics

Chairs: J. Gallinat (D) and D. Rujescu (D)

- I73** Candidate genes in schizophrenia
W. Maier (D)
- I74** Intermediate phenotypes in psychiatry: Meeting the expectations?
J. Gallinat (D)
- I75** Genome-wide association studies in Bipolar Disorder and beyond
T.G. Schulze (US)
- I76** The role of genetics in schizophrenia
D. Rujescu (D)

Animal models

Chairs: M. Hamon (F) and G. Juckel (D)

- I77** What we learned and what can be expected from animal models of depressive disorders
L. Lanfumey (F)
- I78** Epidemiology-driven neurodevelopmental animal models of schizophrenia
U. Meyer (CH)
- I79** Animal models of addictive disorders
B. Boutrel (CH)
- I80** Stress-induced ADHD symptoms in adolescence: Structural and neurochemical changes in the prefrontal cortex of rodents
K. Braun (D)

Anxiety

TH-Saal

Chairs: J. Deckert (D) and M. Anseau (B)

I81 A chemosensitive anxiety response: Carbon dioxide triggers inborn distress in healthy humans

E. Griez (NL)

I82 Gene-environment interactions in anxiety: The caffeine example

J. Deckert (D)

I83 Brain imaging in panic disorder

T. Kircher (D)

I84 Neural correlates of cognitive flexibility in obsessive-compulsive disorder

P.L. Remijnse (NL)

18.30 Poster Prize and Young Investigator Awards

WB-Saal

18.45 Closure
A. Heinz (D)



- P1** Converging evidence for CDH13 as a candidate gene for ADHD
Reif A., Nguyen T., Weissflog L., Jacob C., Romanos M., Schäfer H., Warnke A., Lesch K.-P. (D)
- P2** Impulsivity in adults attention disorders
Bouchez J., Caci H., Baylé F. (F)
- P3** Response inhibition, working memory and response time variability as attention-deficit/hyperactivity endophenotypes – An event-related potentials study
Geißler J., Romanos M., Warnke A., Fallgatter A., Lesch K.-P. (D)
- P4** Acute treatment with cannabinoid receptor agonist WIN55212,2 improves prepulse inhibition in psychosocially stressed mice
Brzózka M., Fischer A., Falkai P., Havemann-Reinecke U. (D)
- P5** Antidepressant-like effect of ketanserin in prenatal stressed female offspring with post-traumatic stress disorder
Fedotova J., Pivina S., Shamolina T., Ordyan N. (RU)
- P6** Dopamine dysregulation syndrome
Denizot H., Zengin Y., Durif F., Llorca P.M. (F)
- P7** Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in rats – A pilot study
Klein J., Eberhardt C., Männer A., Baldassarri J., Morgenstern R., Winter C. (D)
- P8** Netrin G1 polymorphisms in cocaine and alcohol codependence vulnerability: From mice to men
Kelai K., Maussion G., Boni C., Ramoz N., Simonneau M., Gorwood P. (F)
- P9** Effects of intravenous lorazepam on EEG power spectrum and fMRI functional connectivity
Wollweber B.T., Kiem S.A., Hoehn D., Andrade K., Spoomaker V., Holsboer F., Czisch M., Sämann P.G. (D)
- P10** Korean medication algorithm for generalized anxiety disorder 2009: Consensus of treatment strategy in case of partial response or non-response
Suh H.S., Lee J.Y., Lee S.H., Kim M.S., Yang J.C., Kim C.H., Yu B.H. (KR)
- P11** The relationship between chronic low back pain and chronic posttraumatic stress disorder
Bras M., Loncar Z., Gregurek R., Boban M., Milunovic V., Kalenic B. (HR)

- P12** “...If I only had a heart” - Empathy in autism revisited – Same affective reaction, but lack of emotion recognition and perspective taking
Michel T.M., Herholz S., Schneider F., Habel U. (D)
- P13** Altered neural network supporting personal familiarity in patients with amnesic mild cognitive impairment
Jurjanz L., Donix M., Meyer S., Amanatidis E.C., Holthoff V.A. (D)
- P14** Exosome secretion bypasses lysosomal storage of cholesterol in Niemann-Pick type C disease
Schneider A. (D)
- P15** Insulin receptor involvement in Alzheimer’s disease
Bartl J., Meyer A., Riederer P., Grünblatt E. (D & CH)
- P16** Lipopolysaccharide and phagocytosis induce differential A_β peptide signatures in human phagocytes
Spitzer P., Herrmann M., Klafki H.W., Lewczuk P., Kornhuber J., Wiltfang J., Maler J.M. (D)
- P17** Neuropsychological differences between Alzheimers disease patients with and without co-morbid depression are related to altered neurotrophins
Rapp M., Hofrichter N., Dick S., Hellweg R., Heinz A. (D)
- P18** NGF serum levels and NGF gene promoter methylation are altered in patients with alcohol dependence
Muschler M.A., Heberlein A., Frieling H., Kornhuber J., Hillemacher T., Bleich S. (D)
- P19** Polymorphism of the long polyglutamine tract in the human androgen receptor and the methylation status of the POMC gene promoter are inversely correlated in craving in alcohol dependence
Muschler M., Lenz B., Frieling H., Kornhuber J., Hillemacher T., Bleich S. (D)
- P20** Association of the brain-derived neurotrophic factor (BDNF) VAL66MET polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: In vivo evidence for effects on the glutamate system
Hasan A., Falkai P., Scherk H., Wobrock T., Schneider-Axmann T., Ekawardhani S., Backens M., Schmitt A., Reith W., Meyer J., Gruber O. (D)
- P21** The catechol-o-methyl transferase VAL158MET polymorphism and its influence on reward processing in major depressive disorder
Hägele C., Sterzer P., Stoy M., Schlagenhaut F., Friedel E., Puls I., Heinz A., Ströhle A. (D)
- P22** The schizophrenia susceptibility gene neuregulin-1 is associated with prefrontal grey matter volumes
Trost S., Gruber O., Wobrock T., Scherk H., Ekawardhani S., Focke N., Zilles D., Schmitt A., Reith W., Meyer J., Falkai P. (D)

- P23** Improved long-term memory performance for reinforced reward-predicting stimuli - A pilot study
Charlet K., Wüstenberg T., Schneider-Hassloff H., Kensche M., Schott B.H., Wrase J., Heinz A. (D)
- P24** Non-right handedness and free serum testosterone levels in detoxified alcoholics - A concept of dynamic vulnerability?
Sperling W., Biermann T., Reulbach U., Kornhuber J. (D)
- P25** A new approach for the assessment of the human mirror neuron system: "ACTION" AND "Action observation" measured by fNIRS
Herrmann M.J., Koehler S., Egetemeir J., Stenneken P., Pauli P., Fallgatter A.J. (D)
- P26** Agmatinase, an enzyme which inactivates the endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders
Bernstein H.G., Stich C., Wick M., Steiner J., Bogerts B., Veh R., Laube G. (D)
- P27** Combative HF-rTMS treatment, for a bipolar patient, following unsuccessful ECT
Zeeuws D., Baeken C. (B)
- P28** Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomised, double-blind study
Pilhatsch M., Wolf R., Bauer M. (D)
- P29** Dissociation of psychopathological and neuropsychological symptoms in major depression: Persistence of cognitive deficits and altered neuronal activity in the course of treatment
Grimm S., Boeker H. (CH & D)
- P30** Early changes of serum brain-derived neurotrophic factor (S-BDNF) are associated with final changes of S-BDNF and depression severity in men and women with major depression during short-term antidepressant treatment
Wagner S., Schlicht K.F., Peetz D., Borysenko L., Hiemke C., Lieb K., Tadi_ A. (D)
- P31** Formalized recommendations on the treatment of acute bipolar depression of french association of biological psychiatry
Samalin L., Guillaume S., Martin P., Abbar M., Meynard J.A., Gay C., Courtet P. (F)
- P32** Gustatory and olfactory functions in patients with major depression treated with vagus nerve stimulation (VNS)
Thuerauf N., Kornhuber J., Sperling W. (D)

- P33** Neural and behavioral correlates of social interaction of chronically depressed patients
Schnell K., Walther S., Bluschke S., Schoepf D., Schramm E., Walter H. (D)
- P34** Non-reward and punishment as related to anxiety and impulsiveness in abstinent alcoholics
Baars M., Netter P. (D)
- P35** Oculometry as indicator of treatment efficacy in MDD
Malsert J., Chauvin A., Guyader N., Szekely D., Polosan M., Holtzmann J., Bougerol T., Marendaz C. (F)
- P36** The use of chronotherapy in unipolar and bipolar depression
Michalopoulos G., Aubry J.M., Bondolfi G. (CH)
- P37** Turning a blind eye to sadness: Attentional deployment is an effective emotion regulation strategy in major depression
Herrmann M.J., Georgs M., Rebhahn A., Jarczok T., Kulpok C., Gajewska A., Mühlberger A., Pauli P., Fallgatter A. (D)
- P38** Use of antidepressants in psychiatric in-patients in clinical reality
Degner D., Konstantinidis A., Horvath A., Rütger E., Grohmann R. (D, A & CH)
- P39** Effects of extinction training on mesolimbic cue-reactivity in alcohol dependence
Vollstädt-Klein S., Löber S., Kiefer F. (D)
- P40** Modulation of functional activation patterns by disorder-specific stimuli before and after CBT in patients with agoraphobia and panic disorder
Wittmann A., Guhn A., Schlagenhaut F., Fydrich T., Siegmund A., Stoy M., Pfeleiderer B., Lueken U., Bruhn H., Rehbein H., Fehm L., Konrad C., Kircher T., Reinhardt I., Wittchen H.-U., Ströhle A. (D)
- P41** Behavioral control in adult ADHD: Evidence from a simultaneous EEG/fMRI-study
Karch S., Thalmeier T., Lutz J., Ceroveckí A., Hock B., Opgen-Rhein M., Leicht G., Hennig-Fast K., Meindl T., Mulert C., Riedel M., Pogarell O. (D)
- P42** Behavioural inhibition and decision making processes in patients with impulse control deficits
Pogarell O., Merz H., Koller G., Segmiller F., Riedel M., Karch S. (D)
- P43** Effects of long-term prefrontal repetitive transcranial magnetic stimulation on motor – cortical excitability
Hasan A., Guse B., Heine Y., Heyer S., Schneider-Axmann T., Falkai P., Wobrock T. (D)

- P44** MEG does not reveal impaired sensory gating in first-episode schizophrenia
Bachmann S., Weisbrod M., Röhrig M., Rupp A. (D)
- P45** Motivational salience specifically modulates repetition suppression in the anterior hippocampus
Zweynert S., Pade J.P., Wüstenberg T., Seidenbecher C., Duzel E., Schott B. (D & UK)
- P46** New research potential of mismatch negativity: Optimized multifeature paradigms and other applications in clinical psychiatry
Norra C., Thoennesen H. (D)
- P47** Psychophysiological investigation: Lie detection and sexology
Kamenskova M. (RU)
- P48** Sleep deprivation does not accelerate the inhibitory effects of acute hypoglycemia on pituitary-gonadal and -thyroid axis activity in healthy men
Jauch-Chara K., Schmid S.M., Hallschmid M., Oltmanns K.M., Schultes B. (D & CH)
- P49** White matter microstructural alterations of the extrastriate visual cortex in women with anorexia nervosa as detected by voxel-based diffusion tensor imaging
Peschel T., Fischer J., Engelhorn T., Bleich S., de Zwaan M., Frieeling H. (D)
- P50** Clinical pharmacotherapy in borderline personality disorder-evidence based treatment vs. clinical reality
Wedekind D., Rütger E., Degner D., Engel K., Falkai P., Havemann-Reinecke U., Bandelow B. (D)
- P51** Decreased left subgenual anterior cingulate cortical activity during withdrawal-related emotions in unipolar depressed female patients
Baeken C., De Raedt R., Van Schuerbeek P., De Mey J., Vanderhasselt M.A., Luyckaert R. (B)
- P52** Effects of dopaminergic mechanisms of age-related changes in functional activation during reversal learning
Schlagenhauf F., Rapp M.A., Hyus Q., Deserno L., Beck A., Kalbitzer J., Kumakura Y., Buchholz H.G., Plotkin M., Heinz A. (D, UK & J)
- P53** Enhanced brain availability of domperidone by a macromolecular drug carrier system
Knoth C., Barz M., Hemmelmann M., Hiemke C., Rösch F., Schmitt U., Zentel R. (D)

- P54** Genetic polymorphisms of serotonergic and dopaminergic neurotransmission impact on working memory performance in healthy subjects
Zilles D., Ponto C., Papassotiropoulos A., Falkai P., Gruber O. (D & CH)
- P55** Is alexithymia a risk for relapse on alcoholism? Prospective study on 56 alcohol dependent patients
Zaplana F., Brousse G., Picard V., Arnaud B., Planche F., Karim M., Geneste J., Blanc O., Malet L., Llorca P.M. (F)
- P56** Neural networks underlying recognition of personal familiarity in younger and older subjects
Meyer S., Donix M., Jurjanz L., Amanatidis E.C., Poettrich K., Petrowski K., Baeumler D., Herold U., Smolka M., Holthoff V.A. (D)
- P57** No association of alcohol dependence with HOMER 1 and 2 genetic variants
Preuss U.W., Ridinger M., Rujescu D., Fehr C., Koller G., Wodarz N., Bondy B., Soyka M., Wong W.M., Zill P. (D & CH)
- P58** Pathology supported genetic testing and personalized intervention in demyelinating diseases: Iron and folate
*Van Rensburg S.J.¹, Kotze M.J.¹, Hon G.M.², Jalali M.¹, Erasmus R.T.¹
¹Dept. of Pathology, NHLS and University of Stellenbosch, Cape Town;
²Biomedical Sciences, Cape Peninsula University of Technology, Cape Town, South Africa*
- P59** Personality disorders improved after arachnoid cyst neurosurgery, then rediagnosed as 'minor' organic personality disorders
Bechter K., Wittek R., Seitz K., Antoniadis G. (D)
- P60** Psychosis caused by neurosyphilis - not to be forgotten
Sheldrick A.J., Michel T.M. (D)
- P61** Psychotropics and pregnancy
Lahlou N. (MA)
- P62** Rapunzel syndrome: A case report
Nada A. (MA)
- P63** Right prefrontal HF-RTMS attenuates right amygdala processing of negatively valenced emotional stimuli in healthy females
Baeken C., De Raedt R., Van Schuerbeek P., Vanderhasselt M.A., De Mey J., Luyckaert R. (B)
- P64** Sweet taste questionnaire in addict versus depressed patients: Preliminary results
Vederine F.E., Vorspan F., Zerdazi E.H., Dupuy G., Lépine J.P. (F)

- P65** The course of tobacco craving during smoking cessation in psychiatric in-patients
Mehtelli W, Dupuy G, Vorspan F, Lépine J.P. (F)
- P66** Treatment of obsessive-compulsive disorder with quetiapine in monotherapy – A pilot study
Degner D., Bleich S. (D)
- P67** Zolpidem and anoxic encephalopathy – Prolonged treatment response
Kaufman K.R., Bagayogo I., Franzen J.L., Kaufman I.H. (USA)
- P68** Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers
Bondolfi G., Choong E., Etter M., Oneda B., Tayebi H., Aubry J.M., Eap C.B. (CH)
- P69** Altered emotion processing in schizophrenia patients – A functional imaging study
Pankow A., Friedel E., Beck A., Rapp M., Heinz A., Schlagenhauf F. (D)
- P70** Clinical evaluation of theta burst stimulation on the resistant auditory hallucinations and its impact on cognitive function and neuroexcitability - Pilot study
Sidhoumi D., Braha S., Bouaziz N., Benadhira R., Januel D. (F)
- P71** Cognitive functioning with respect to genetic underpinnings of immune activation in schizophrenia
Frydecka D., Karabon L., Pawlak E., Beszlej A. (PL)
- P72** Frontal volume increase after aerobic exercise in schizophrenia
Malchow B., Falkai P., Pajonk F.G., Reith W., Sun F., Cannon T.D., Wobrock T. (D & USA)
- P73** Human endogenous retrovirus in schizophrenia: A new avenue of research at the gene-environment interface
Perron H., Leboyer L. (CH & F)
- P74** Imaging thought insertion in schizophrenia
Kühn S., Gallinat J., Vosgerau G., Haggard P., Voss M. (UK, D & B)
- P75** Male sexual dysfunction in treatment with antipsychotics
Boatas F., de Miguel L., French E. (E)
- P76** Mismatch negativity discriminates between deficit and non-deficit syndrome in recent-onset schizophrenia
Bodatsch M., Brockhaus-Dumke A., Müller R., Klosterkötter J., Ruhrmann S. (D)
- P77** Nicotine dependence among a group of Iraqi schizophrenic patients
Twana A.R., Muhyadin A.S. (IQ)

- P78** No volumetric brain differences between first-episode schizophrenia patients with and without cannabis abuse
Malchow B., Falkai P., Gruber O., Reith W., Wobrock T. (D)
- P79** Perceptual, working memory and executive processes in schizophrenia: Relationship to fluid intelligence
Rapp M., Reichenberg A. (D & UK)
- P80** Transcranial direct current stimulation (TDCS) in the treatment of refractory auditory hallucinations in schizophrenia
Brunelin J., Mondino M., Haesebaert F., d'Amato T., Saoud M., Poulet E. (F)
- P81** Volitional motor activity in schizophrenia is related to baseline perfusion in the cingulate and prefrontal cortex
Walther S., Horn H., Federspiel A., Razavi N., Dierks T., Strik W., Müller T.J. (CH)
- P82** White matter integrity of motor tracts correlates with volitional motor activity in schizophrenia
Walther S., Horn H., Federspiel A., Razavi N., Dierks T., Strik W., Müller T.J. (CH)
- P83** Is early relapse into alcohol drinking predictable by sleep disturbance, cortisol secretion or overnight memory consolidation?
Friedrich A., Hartmann Y., Machner M., Ehrental D., Junghanns K. (D)
- P84** Poor sleep is related to parenting stress and impaired postpartum bonding in depressed mothers
Mikoteit T., Keller N.M., Brand S., Sievers E., Riecher-Rössler A., Holsboer-Trachsler E., Hatzinger M. (CH)
- P85** Stress, aggression, and social information processing
Bertsch K., Böhnke R., Kruk M.R., Naumann E. (D & NL)
- P86** The influence of emotional intensity on thalamic circuits – Evidence from high resolution fMRI
Walter M., Stadler J., Eckert U., Steiner J., Buchmann J., Bogerts B., Metzger C. (D)
- P87** Clozapine plasma level monitoring for prediction of relapse in schizophrenic outpatients
Stieffenhofer V., Saglam H., Schmidtmann I., Silver H., Konrad A., Hiemke C. (D & IL)
- P88** Long term treatment of schizophrenic psychoses with flupentixol decanoate: Results of a non-interventional study
Laux G., Steinmann C., Glaser T. for the Study Group (D)
- P89** 5-HTT genotype effect on reward-related modulation of medial prefrontal activity in major depression
Sterzer P., Hägele C., Stoy M., Schmack K., Schlagenhaut F., Puls I., Heinz A., Ströhle A. (D)

- P90** Early increase of brain-derived neurotrophic factor (BDNF) serum levels in individual patients with major depression during antidepressant treatment predicts final BDNF increase with sensitivity and specificity
Schlicht K.F., Wagner S., Peetz D., Borysenko L., Krannich D., Bernius A., Hiemke C., Lieb K., Tadi_A. (D)
- P91** Impact of high frequency repetitive transcranial magnetic stimulation on fine motor function in therapy resistant major depression
Schrijvers D., Baeken C., De Raedt R., Sabbe B. (B)
- P92** Individualized music-focussed audio therapy for the treatment of depression – A controlled double-blind study and proof of efficacy
Brandes V., Terris D.D., Fischer C., Jarczok M.N., Ottowitz G., Titscher G., Fischer J.E., Thayer J.F. (A, D & USA)
- P93** Plasma concentrations of citalopram in depressed inpatients and clinical improvement in a naturalistic setting
Ostad Haji E., Tadic A., Dragicevic A., Müller M.J., Grasmäder K., Rao M.L., Laux G., Hiemke C. (D)
- P94** Successful ECT treatment after relapse during VNS therapy
Santermans L., Vanderbruggen N., Baeken C. (B)
- P95** The effectivity of vagus nerve stimulation (VNS) in treatment-resistant depression and comorbid personality disorder – A case series
Wolff-Menzler C., Falkai P., Hasan A., Dougherty T., Wobrock T. (D)
- P96** Kratom and alcohol dependence: Clinical symptoms and withdrawal treatment – A case report
Ziebolz N., Bloch S., Neurath H., Havemann-Reinecke U. (D)
- P97** S100B and homocysteine in the acute alcohol withdrawal syndrome
Wedekind D., Neumann K., Falkai P., Malchow B., Engel K., Jamrozinski K., Havemann-Reinecke U. (D)
- P98** The long QT syndrome in a psychiatric inpatients specific unit for difficult patients: Prevalence, risk factors and treatment implications
Chaumartin N., Lukat S., Garriguet P., Urrea P.-R., Lachaux B. (F)
- P99** Gender identity disorders: Personalized care for patients seeking sex reassignment surgery
Gallarda T., Rari E., Coussinoux S., Bourdel M.C., Machefaux S., Olié J.P. (F)
- P100** The psychological meaning of subliminal stimuli of different durations
Alawi E.M., Zvyagintsev M., Mathiak K., Mathiak K.A. (D & NL)
- P101** Interactive verbal and emotional communication during fMRI
Isman D., Klasen M., Zvyagintsev M., Mathiak K. (D)

Registration

Registration Fees

| | EARLY Until January 31 | LATE Until March 31 | ON SITE |
|--------------------|---------------------------|------------------------|----------|
| Member* | € 400,00 | € 450,00 | € 500,00 |
| Non Member | € 450,00 | € 500,00 | € 550,00 |
| Resident/Trainee** | € 250,00 | € 250,00 | € 250,00 |

*Applicable for members of one of the organising societies: BCNBP – AFPB – DGPB – ÖGPB – SGBP.

**Proof of trainee status is to be sent to Medicongress (fax +32 9 344 40 10). Without this proof the Non Member fee will be charged.

Important

Pre-registration closes on May 25. In order to avoid queuing up at the registration desk of the Meeting, it is advisable to register before May 25.

The registration fee for participants includes

- Participation in all scientific sessions
- Participation in the satellite symposia organised by the Industry
- Congress bag with the Programme and Abstracts, tourist info and meeting related documents
- Access to the exhibition
- Lunch and coffee breaks
- Get-Together Party on Wednesday evening, June 2

How to Register

Register, pay and book hotel accommodation online at www.webp2010.eu.

The online registration and payment form is secured so that credit card information can be submitted safely.

Immediately after registration an automatic confirmation of your registration is sent by email. If you do not receive this automatic confirmation your registration has not been made successfully.

Confirmation

Medicongress will send a formal confirmation by email after receipt of payment.

Payment

All payments are to be made in Euro, net of bank charges and commissions for the receiver. Payment is to be made by:

- Bank transfer
Account number: 123-6800072-20
Account Name: WEBP PSYCHIATRY
SWIFT: BKCP BE B1 OBK - IBAN: BE28 1236 8000 7220
Bank address: OBK Bank, Graaf Van Vlaanderenplein 19, 9000 Gent, Belgium
- Credit Card: All major credit cards are accepted.

Cancellations

Participants canceling their registration before May 1, 2010, will receive a 50% refund. There will be no refunds for cancellations received after this date.

Cancellations must be confirmed in writing to the Organising Secretariat.


All refunds will be processed after the Meeting.

Name substitutions are accepted at any time at an extra charge of € 75,00.

Hotel Accommodation

Please check the website www.webp2010.eu for the hotel list and rates.

Organising Secretariat



MEDICONGRESS

Kloosterstraat 5, B-9960 Assenede

Phone: +32 (0)9 344 39 59, Fax: +32 (0)9 344 40 10

Contact person: Mrs Els Vertriest - els@medicongress.com

www.medicongress.com

www.webp2010.eu

General Information

The city

Berlin is the capital of Germany and its largest city, with more than 3,400,000 inhabitants. On the day of German reunification, October 3, 1990 Berlin became an independent city-state like Hamburg and Bremen. Reunited Federal Germany consists of a total of 16 federal states, known as 'Länder'.

The city has no definite centre and pockets of attractions are dotted all over. The densest array of sights lies to the east of the Brandenburg Gate, on either side of Unter den Linden. West Berlin's centre has less to offer. Nevertheless visitors should take a look at the broken shard of a church, the Kaiser Wilhelm Gedächtniskirche, which serves as a brutal reminder of World War II. The nearby Zoo and Aquarium also provide a happy distraction.

Berlin boasts over 170 museums and galleries: on offer are unmissable artefacts such as the Pergamon's treasures of antiquity at the Museum Island, contemporary art and modernist classics such as the Bauhaus building. Daniel Libeskind's Jewish Museum, built after reunification, is one of the memorable highlights of the New Berlin. From Nefertiti's bust to a speck of the Wall at Checkpoint Charlie, Berlin's museums bring its unique character and history to life.

Congress Venue

Rathaus Schöneberg,
John-F.-Kennedy-Platz,
10820 Berlin
Metro Exit: Schöneberg, Line U4

Rathaus Schöneberg was the seat of the West Berlin city government during the Cold War and is probably best known as the location where John F. Kennedy made his famous 'Ich bin ein Berliner' speech.

At the time of its construction, between 1911 and 1914, the town of Schöneberg was not yet part of Greater Berlin. Following Schönebergs incorporation into Berlin in 1923, the Rathaus was just one of many borough town halls. Following the Second World War and the division of Berlin, it became the "provisional" seat of West Berlin's government, a situation which continued right up until reunification in 1990. It was home to both the parliament and the Senate (mayoral cabinet).

Following reunification Berlin was once again governed from the traditional Rotes Rathaus (Red City Hall), and Rathaus Schöneberg reverted to its original function as the town hall for the Borough of Schöneberg-Tempelhof.

The clock tower houses the Freiheitsglocke (Freedom Bell or Liberty Bell), donated by the people of the United States to Berlin in 1950. It can be heard at midday every day.

The square in front of the building was named John-F.-Kennedy-Platz following the President's assassination in 1963. On weekends it is home to a flea-market.

The John F. Kennedy Speech

John F. Kennedy made his famous 'Ich bin ein Berliner' speech during a visit to Berlin on June 26, 1963 (www.youtube.com).

Congress Dates

2 – 4 June 2010

Language

The official language of the Meeting is English.

Accreditation

An application for accreditation units (CME credits) has been submitted to the UEMS.

Liability

By registering for the 3rd Meeting and/or by participating in the exhibition held in conjunction with the 3rd Meeting, participants and exhibitors agree that neither the Organising Societies nor the Organising Committee & Organising Secretariat assume any liability. Participants and exhibitors are advised to organise their own health, travel and personal insurances.

